Trial · NCT02160782
Adverse events1,026
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,026
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypertension | Vascular disorders | Open-label Period: Maralixibat (LUM001) | 1 | 31 | 1 |
| other | Hypertension | Vascular disorders | Randomized Withdrawal Period: MRX | 0 | 13 | 0 |
| other | Hypertension | Vascular disorders | Randomized Withdrawal Period: Placebo | 1 | 16 | 1 |
| other | Hypertension | Vascular disorders | After Randomized Withdrawal Period: Maralixibat | 0 | 29 | 0 |
| other | Hypertension | Vascular disorders | Long-term Extension Period: Maralixibat | 0 | 23 | 0 |
| other | Hypertension | Vascular disorders | Safety Population | 2 | 31 | 2 |
| other | Subclavian artery stenosis | Vascular disorders | Open-label Period: Maralixibat (LUM001) | 0 | 31 | 0 |
| other | Subclavian artery stenosis | Vascular disorders | Randomized Withdrawal Period: MRX | 0 | 13 | 0 |
| other | Subclavian artery stenosis | Vascular disorders | Randomized Withdrawal Period: Placebo | 0 | 16 | 0 |
| other | Subclavian artery stenosis | Vascular disorders | After Randomized Withdrawal Period: Maralixibat | 0 | 29 | 0 |
| other | Subclavian artery stenosis | Vascular disorders | Long-term Extension Period: Maralixibat | 1 | 23 | 1 |
| other | Subclavian artery stenosis | Vascular disorders | Safety Population | 1 | 31 | 1 |
| other | Gastrostomy | Surgical and medical procedures | Open-label Period: Maralixibat (LUM001) | 0 | 31 | 0 |
| other | Gastrostomy | Surgical and medical procedures | Randomized Withdrawal Period: MRX | 0 | 13 | 0 |
| other | Gastrostomy | Surgical and medical procedures | Randomized Withdrawal Period: Placebo | 0 | 16 | 0 |
| other | Gastrostomy | Surgical and medical procedures | After Randomized Withdrawal Period: Maralixibat | 1 | 29 | 1 |
| other | Gastrostomy | Surgical and medical procedures | Long-term Extension Period: Maralixibat | 0 | 23 | 0 |
| other | Gastrostomy | Surgical and medical procedures | Safety Population | 1 | 31 | 1 |
| other | Neoplasm skin | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Open-label Period: Maralixibat (LUM001) | 0 | 31 | 0 |
| other | Neoplasm skin | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Randomized Withdrawal Period: MRX | 0 | 13 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02160782/events